{
  "id": 2235721,
  "title": "Earnings call transcript: eXoZymes posts q2 2026 loss as launch plans advance",
  "url": "https://urgent.news/2026/08/20/earnings-call-transcript-exozymes-posts-q2-2026-loss-as-launch-plans",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-20T22:07:17.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/transcripts/earnings-call-transcript-exozymes-posts-q2-2026-loss-as-launch-plans-advance-93CH-4870604"
  },
  "original_language": "en",
  "account": "eXoZymes Inc. reported a second quarter net loss of $2.88 million on February 28, 2026. The pre-revenue biotech company ended the quarter with $5.65 million in cash and reported its first half operating expenses of $5.34 million. The company's lead product, NCT, made significant progress, with a pilot-scale campaign in March producing over 500 grams of high-purity material. Management highlighted a 10x productivity improvement in NCT, generated through both process efficiencies and AI-enhanced biomanufacturing. The company expects to maintain sufficient liquidity to fund operations through the end of 2026. eXoZymes' shares rose 10% in regular trading to $7.04, then fell 7.5% after hours to $6.51. The company's stock is currently valued at $58.3 million, but analysts suggest it may be overvalued relative to its Fair Value estimate.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Earnings call transcript: Flux Power posts q4 2026 revenue miss, shares swing lower",
        "url": "https://urgent.news/2026/08/20/earnings-call-transcript-flux-power-posts-q4-2026-revenue-miss-shares",
        "published": "2026-08-20T21:11:50.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}